EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of nebulized liposomal amphotericin B and posaconazole as antifungal prophylaxis in patients with severe SARS-CoV2 infection in intensive care unit

Benedetta Fumarola, Liana Signorini, Silvia Lorenzotti, Paola Lanza, Barbara Saccani, Evelyn Van Hauwermeiren, Alice Mulè, Simone Piva, Matteo Rota, Francesco Zuccalà, Francesco Antonio Rasulo, Matteo Filippini und 3 weitere

Infection · 2024

DOI: 10.1007/s15010-024-02234-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection, 2024. Verfasst von Benedetta Fumarola und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Infectious Diseases, ASST Spedali Civili, Brescia, Italy. benni.fumarola@gmail.com. Hauptthemen laut MEDLINE: Antifungal Agents, Amphotericin B, Intensive Care Units, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Brescia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

COVID-19 associated pulmonary aspergillosis (CAPA) is common and linked with high fatality rates. To assess the impact on the incidence and outcome of CAPA of an antifungal prophylaxis (AFP) we compared two cohorts of COVID-19 patients admitted to intensive care units (ICU) in Brescia, Italy, from January to August 2021.

Methods

The study cohort included all mechanically ventilated patients observed between April 2021 and August 2021 with SARS-CoV-2-pneumonia, who received AFP with oral posaconazole (200 mg every 6 h) and nebulized liposomal amphotericin B (50 mg every 2 weeks) from ICU admission to 7 days after discharge or, if applicable, until tracheostomy removal. The control cohort included COVID-19 patients admitted to the same ICU between January and March 2021 who did not receive any AFP. Subjects with CAPA at ICU admission were excluded.

Results

We included 270 patients, of whom 64 (23.7%) received AFP. In patients in the study group, CAPA-related mortality was significantly reduced (29% vs. 48% p = 0.04), as well as the incidence of CAPA (3.1% vs 12.1%, p = 0.03). Patients who developed CAPA were older (mean of 70-y-old vs 63-y-old, p < 0.001). One subject discontinued posaconazole due to an adverse reaction. Among the 46 patients who received it, only one patient reached an effective plasma concentration of posaconazole.

Conclusion

AFP was associated with reduced incidence and mortality from CAPA and was well tolerated in patients with severe COVID-19. Posaconazole concentrations below the efficacy threshold in almost all patients may be attributable to drug interactions and prompt further studies to define its clinical significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAmphotericin BIntensive Care UnitsCOVID-19HumansMaleFemaleMiddle AgedAgedSARS-CoV-2ItalyTriazolesPulmonary AspergillosisCohort Studies

Stichwörter der Autor:innen

Antifungal prophylaxisCAPACOVID-19Intensive care unit

Substanzen

posaconazoleAntifungal AgentsAmphotericin Bliposomal amphotericin BTriazoles

Autor:innen und Institutionen

  • Clinic of Infectious Diseases, ASST Spedali Civili, Brescia, Italy. benni.fumarola@gmail.com.
  • Clinic of Infectious Diseases, ASST Spedali Civili, Brescia, Italy.
  • Department of Clinical and Experimental Medicine, University of Brescia, Brescia, Italy.
  • Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
  • Department of Anesthesia, Critical Care and Emergency, Spedali Civili University Hospital, Brescia, Italy.
  • Department of Molecular and Translational Medicine, Università degli Studi di Brescia, Brescia, Italy.

Förderung

  • Università degli Studi di Brescia

Zitieren

APA

Fumarola, B., Signorini, L., Lorenzotti, S., Lanza, P., Saccani, B., Van Hauwermeiren, E., Mulè, A., Piva, S., Rota, M., Zuccalà, F., Rasulo, F. A., Filippini, M., Bertazzoli, A., Del Fabro, G., & Matteelli, A. (2024). Use of nebulized liposomal amphotericin B and posaconazole as antifungal prophylaxis in patients with severe SARS-CoV2 infection in intensive care unit. Infection. https://doi.org/10.1007/s15010-024-02234-9

Vancouver

Fumarola B, Signorini L, Lorenzotti S, Lanza P, Saccani B, Van Hauwermeiren E, et al. Use of nebulized liposomal amphotericin B and posaconazole as antifungal prophylaxis in patients with severe SARS-CoV2 infection in intensive care unit. Infection. 2024. doi:10.1007/s15010-024-02234-9

BibTeX
@article{Fumarola2024,
  author = {Fumarola, Benedetta and Signorini, Liana and Lorenzotti, Silvia and Lanza, Paola and Saccani, Barbara and Van Hauwermeiren, Evelyn and Mulè, Alice and Piva, Simone and Rota, Matteo and Zuccalà, Francesco and Rasulo, Francesco Antonio and Filippini, Matteo and Bertazzoli, Alberto and Del Fabro, Giovanni and Matteelli, Alberto},
  title = {Use of nebulized liposomal amphotericin B and posaconazole as antifungal prophylaxis in patients with severe SARS-CoV2 infection in intensive care unit},
  journal = {Infection},
  year = {2024},
  doi = {10.1007/s15010-024-02234-9}
}
Kostenlos starten →